Compare Mesoblast Limited (MESO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Oxford Lane Capital Corp — how do they compare? Mesoblast Limited trades at $17.03 (market cap $2.21B), while Oxford Lane Capital Corp trades at $9.39 (market cap $909.61M). The key difference: Mesoblast Limited is far larger — about 2.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | OXLC | |
|---|---|---|
Market Cap | $2.21B | $909.61M |
Sector | Technology | Financials |
52-Week High | $20.96 | $18.75 |
52-Week Low | $12.88 | $8.15 |
Enterprise Value | $2.21B | — |
Dividend Yield | — | 25.76% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
